UBS Group AG lowered its stake in Emergent Biosolutions, Inc. (NYSE:EBS) by 6.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 33,673 shares of the biopharmaceutical company’s stock after selling 2,385 shares during the period. UBS Group AG owned approximately 0.08% of Emergent Biosolutions worth $978,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of EBS. Vanguard Group Inc. boosted its stake in shares of Emergent Biosolutions by 6.7% in the first quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock worth $109,574,000 after buying an additional 238,194 shares during the period. Dimensional Fund Advisors LP boosted its stake in Emergent Biosolutions by 1.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,053,683 shares of the biopharmaceutical company’s stock worth $59,639,000 after buying an additional 28,365 shares during the last quarter. Aberdeen Asset Management PLC UK boosted its stake in Emergent Biosolutions by 29.6% in the first quarter. Aberdeen Asset Management PLC UK now owns 1,618,576 shares of the biopharmaceutical company’s stock worth $47,003,000 after buying an additional 369,908 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Emergent Biosolutions by 1.4% in the first quarter. Acadian Asset Management LLC now owns 1,400,091 shares of the biopharmaceutical company’s stock valued at $40,658,000 after buying an additional 18,739 shares in the last quarter. Finally, Snyder Capital Management L P boosted its stake in Emergent Biosolutions by 17.8% in the first quarter. Snyder Capital Management L P now owns 1,134,332 shares of the biopharmaceutical company’s stock valued at $32,941,000 after buying an additional 171,636 shares in the last quarter. Institutional investors own 85.86% of the company’s stock.
Shares of Emergent Biosolutions, Inc. (EBS) traded up 1.00% on Friday, reaching $36.41. The company had a trading volume of 202,269 shares. The stock has a market capitalization of $1.49 billion, a PE ratio of 28.94 and a beta of 1.21. The company has a 50 day moving average price of $34.00 and a 200 day moving average price of $31.13. Emergent Biosolutions, Inc. has a 52-week low of $24.47 and a 52-week high of $36.74.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.31 by $0.08. Emergent Biosolutions had a net margin of 10.36% and a return on equity of 11.92%. The firm had revenue of $116.90 million for the quarter, compared to the consensus estimate of $121.30 million. During the same quarter last year, the company earned $0.16 earnings per share. The firm’s revenue was up 13.5% on a year-over-year basis. On average, equities research analysts anticipate that Emergent Biosolutions, Inc. will post $1.58 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “UBS Group AG Lowers Position in Emergent Biosolutions, Inc. (EBS)” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://stocknewstimes.com/2017/07/30/ubs-group-ag-decreases-position-in-emergent-biosolutions-inc-ebs-updated.html.
Several equities analysts recently weighed in on EBS shares. Zacks Investment Research downgraded Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $39.25.
In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 25,000 shares of the company’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $36.50, for a total transaction of $912,500.00. Following the completion of the sale, the chairman now directly owns 1,630,216 shares in the company, valued at $59,502,884. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 16.50% of the stock is owned by corporate insiders.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
